A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report

Cancer. 1975 Apr;35(4):1083-7. doi: 10.1002/1097-0142(197504)35:4<1083::aid-cncr2820350410>3.0.co;2-k.

Abstract

In 1970, a staging based on surgical resectability of hepatic tumors was devised. Adjuvant chemotherapy with vincristine, 5-fluorouracil, and cyclophosphamide has been given to seven recent cases. Objectives of this study were to set up unified clinical staging and followup; to evaluate the effect of combination chemotherapy on survival in advanced disease; and to evaluate early adjunctive combination chemotherapy in surgically resectable lesions to, hopefully, prevent metastasis. Results to date in seven patients are: no change in the poor prognosis of the three female patients presenting with Stage III-IV hepatocellular carcinoma; the three males with Stage I-II hepatoblastoma have done well and survive the free of disease at 47 months, 44 months, and 28 months; one patient with hepatoblastoma had lung metastasis at diagnosis and died at 7 months with tumor. No toxicity was noted with the use of adjunctive combination chemotherapy following major hepatic resection.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / surgery
  • Child
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use*
  • Doxorubicin / therapeutic use
  • Drug Therapy, Combination
  • Evaluation Studies as Topic
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / therapeutic use*
  • Humans
  • Infant
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / surgery
  • Lung Neoplasms
  • Male
  • Neoplasm Metastasis
  • Time Factors
  • Vincristine / administration & dosage
  • Vincristine / therapeutic use*

Substances

  • Antineoplastic Agents
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Fluorouracil